{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:33:04Z","timestamp":1781008384593,"version":"3.54.1"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004479","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000}}],"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970514"],"award-info":[{"award-number":["81970514"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Key Clinical Specialty","award":["shslczdzk01103"],"award-info":[{"award-number":["shslczdzk01103"]}]},{"name":"Shanghai Municipal Planning Commission of Science and Research Fund","award":["202040111"],"award-info":[{"award-number":["202040111"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Detailed subgroup incidence rates for steatotic liver disease (SLD)-related hepatocellular carcinoma (HCC) are critical to inform practice and public health interventions but remain sparse. We aimed to fill in this gap.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>In a retrospective cohort study of adults with SLD from the United States (US) Merative Marketscan Research Databases (1\/2007 to 12\/2021), we estimated HCC incidence stratified by sex, age, cirrhosis, diabetes mellitus (DM), and a combination of all these 4 factors. We excluded patients with significant alcohol use and chronic viral hepatitis.<\/jats:p>\n<jats:p>We analyzed data from 741,816 patients with SLD (mean age 51.5 \u00b1 12.8 years, 46% male, 14.7% cirrhosis). During a 2,410,166 person-years (PY) follow-up, 1,740 patients developed HCC. The overall HCC incidence yielded 0.72 per 1,000 PY (95% confidence interval [CI, 0.68, 0.75]). The incidence was higher in males (0.95, 95% CI [0.89, 1.01]) compared to females (0.52, 95% CI [0.48, 0.56]) (<jats:italic>p<\/jats:italic> &lt; 0.001). For those with cirrhosis, the incidence was significantly higher at 4.29 (95% CI [4.06, 4.51]) compared to those without cirrhosis (0.14, 95% CI [0.13, 0.16]) (<jats:italic>p<\/jats:italic> &lt; 0.001). Additionally, the incidence was higher in patients with DM (1.19, 95% CI [1.12, 1.26]) compared to those without DM (0.41, 95% CI [0.38, 0.44]) (<jats:italic>p<\/jats:italic> &lt; 0.001). Chronic kidney disease (CKD) was also associated with a higher HCC incidence of 2.20 (95% CI [2.00, 2.41]) compared to those without CKD (0.58, 95% CI [0.55, 0.62]) (<jats:italic>p<\/jats:italic> &lt; 0.001). Similarly, individuals with cardiovascular disease (CVD) had a higher HCC incidence of 1.89 (95% CI [1.75, 2.03]) compared to those without CVD (0.51, 95% CI [0.48, 0.54]) (<jats:italic>p<\/jats:italic> &lt; 0.001). Finally, the incidence of HCC was significantly higher in patients with non-liver cancer (3.90, 95% CI [3.67, 4.12]) compared to those without other cancers (0.29, 95% CI [0.26, 0.31]) (<jats:italic>p<\/jats:italic> &lt; 0.001). On further stratification, HCC incidence incrementally rose by 10-year age intervals, male sex, cirrhosis, and DM, reaching 19.06 (95% CI [16.10, 22.01]) and 8.44 (95% CI [6.78, 10.10]) in males and females, respectively, but only 0.04 for non-diabetic, noncirrhotic aged &lt;40 years patients in both sexes. The main limitation of this methodology is the potential misclassification of the International Classification of Diseases (ICD) codes inherent in claims database studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This nationwide study provided robust granular estimates for SLD-related HCC incidence stratified by several key risk factors. In addition to cirrhosis, future surveillance strategies, prevention, public health initiatives, and future research models should also take into account the impact of sex, age, and DM.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004479","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T17:39:00Z","timestamp":1729877940000},"page":"e1004479","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1704-7086","authenticated-orcid":true,"given":"Rongtao","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie Yeeman","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-4989","authenticated-orcid":true,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"issue":"2","key":"pmed.1004479.ref001","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"MH Le","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"pmed.1004479.ref002","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"MH Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"pmed.1004479.ref003","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis","volume":"20","author":"MH Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"pmed.1004479.ref004","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis","volume":"77","author":"AG Singal","year":"2022","journal-title":"J Hepatol"},{"issue":"12","key":"pmed.1004479.ref005","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"AG Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"pmed.1004479.ref006","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"ME Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"pmed.1004479.ref007","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"ME Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"pmed.1004479.ref008","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"AG Singal","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"pmed.1004479.ref009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression","volume":"20","author":"LA Orci","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"pmed.1004479.ref010","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"JG Stine","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"pmed.1004479.ref011","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"DJH Tan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"pmed.1004479.ref012","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease","volume":"155","author":"F Kanwal","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"pmed.1004479.ref013","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/hep.31157","article-title":"Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes","volume":"72","author":"Y Natarajan","year":"2020","journal-title":"Hepatology"},{"key":"pmed.1004479.ref014","unstructured":"Stanford Center for Population Health Sciences. (2023). MerativeMarketscan Databases (Version 3.0) Data set. Redivis. doi: 10.57761\/kg3j-nh50"},{"key":"pmed.1004479.ref015","unstructured":"Stanford Center for Population Health Sciences. (2023). Merative Marketscan Medicare Supplemental (Version 3.0) Data set. Redivis. doi: 10.57761\/55qs-x460"},{"issue":"3","key":"pmed.1004479.ref016","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/hep.30246","article-title":"Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B","volume":"69","author":"MH Nguyen","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"pmed.1004479.ref017","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jhep.2021.04.042","article-title":"Surveillance of patients with cirrhosis remains suboptimal in the United States","volume":"75","author":"YH Yeo","year":"2021","journal-title":"J Hepatol"},{"key":"pmed.1004479.ref018","article-title":"Hepatocellular carcinoma surveillance\u2014utilization, barriers and the impact of changing aetiology","author":"DQ Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"pmed.1004479.ref019","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity Index: A Critical Review of Clinimetric Properties","volume":"91","author":"ME Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"1","key":"pmed.1004479.ref020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"pmed.1004479.ref021","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"M Omata","year":"2017","journal-title":"Hepatol Int"},{"issue":"4","key":"pmed.1004479.ref022","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0002-9343(96)00197-0","article-title":"Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis","volume":"101","author":"FP Sarasin","year":"1996","journal-title":"Am J Med"},{"issue":"5","key":"pmed.1004479.ref023","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/hep.31845","article-title":"Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study","volume":"74","author":"TG Simon","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"pmed.1004479.ref024","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study","volume":"63","author":"F Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"pmed.1004479.ref025","doi-asserted-by":"crossref","first-page":"1148934","DOI":"10.3389\/fendo.2023.1148934","article-title":"Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets","volume":"14","author":"Y Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"pmed.1004479.ref026","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study","volume":"2","author":"H Hagstrom","year":"2018","journal-title":"Hepatol Commun"},{"issue":"1","key":"pmed.1004479.ref027","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000000329","article-title":"Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)","volume":"78","author":"O Nabi","year":"2023","journal-title":"Hepatology"},{"key":"pmed.1004479.ref028","article-title":"Comparison of characteristics and outcomes in patients with nonalcoholic fatty liver disease who did or didn\u2019t receive liver biopsy","author":"LYK Xinrong Zhang","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"pmed.1004479.ref029","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0168-8278(03)00191-0","article-title":"Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease","volume":"39","author":"G Colloredo","year":"2003","journal-title":"J Hepatol"},{"issue":"6","key":"pmed.1004479.ref030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"RK Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"pmed.1004479.ref031","doi-asserted-by":"crossref","first-page":"90 e1","DOI":"10.1016\/j.amjmed.2014.07.027","article-title":"Racial, social, and clinical determinants of hepatocellular carcinoma surveillance","volume":"128","author":"AG Singal","year":"2015","journal-title":"Am J Med"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004479","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T18:42:07Z","timestamp":1731091327000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004479"}},"subtitle":[],"editor":[{"given":"Gilaad G.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004479","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004479","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}